Clinical trials: Cytomegalovirus
Nonneoplastic Condition
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in…
- Trial name
- NCT00722839
- Testing
- PADRE-CMV fusion peptide vaccine, tetanus-CMV fusion peptide vaccine, agatolimod sodium
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Transplantation Infection, Cytomegalovirus Infection
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals.
- Trial name
- EVERCMV (NCT02328963)
- Testing
- Everolimus, mycophenolic acid
- Where
- 9 sites in France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Bordeaux
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
Cytomegalovirus Disease
Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients
CMV disease is a challenge to the success of renal transplantation. Recently, the investigators analyzed data from 792 renal transplant recipients performed at our hospital between 1999 and 2005.
- Trial name
- NCT01573039
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- University of Sao Paulo General Hospital
Allogeneic Hematopoietic Cell Transplant
A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant
This study is to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in subjects undergoing allogeneic HCT. The occurrence of CMV viremia and immunogenicity are also assessed.
- Trial name
- NCT01903928
- Testing
- ASP0113
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
Infections, Cytomegalovirus
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of…
- Trial name
- LETERCOR (NCT06057194)
- Testing
- Letermovir 240 mg Oral Tablet
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Congenital Infection
Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Because the potential benefit of standard intravenous immunoglobulins (IVIG) - obtained from unselected donor pools including a varying proportion of donors previously exposed to CMV - has not yet been explored in pregnant women…
- Trial name
- NCT01659684
- Testing
- standard intravenous immunoglobulin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Onlus Camillo De Lellis
Cytomegalovirus Infections, HIV Infections
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes < 100 cells/mm3.
- Trial name
- NCT00001038
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 35 sites in United States, Australia and 8 more
- Volunteers
- 1,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infection, Cytomegalovirus Disease
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.
- Trial name
- NCT04129398
- Testing
- Letermovir tablet, Letermovir IV
- Where
- 4 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Viraemia
CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and…
- Trial name
- NCT01883206
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Cytomegalovirus Infection
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202…
- Trial name
- NCT04975893
- Testing
- mRNA-1647
- Where
- 7 sites in United States
- Volunteers
- 135 people
- Sponsor
- ModernaTX, Inc.
Kidney Transplantation, Cytomegalovirus Infections
Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
Cytomegalovirus (CMV) is the most common opportunistic viral pathogen in solid organ transplant receptors (SOTR). In Mexico, the experience using generic immunosuppressants have been demonstrated a wide variation in the…
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, Pharmacokinetics, Therapeutic Equivalency
- Trial name
- NCT03631316
- Testing
- Generic Valganciclovir, Innovative Valganciclovir
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Luis Eduardo Morales Buenrostro
Glioblastoma, Astrocytoma, Grade IV
DC Migration Study for Newly-Diagnosed GBM
This randomized phase II study will assess the impact of pre-conditioning on migration and survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection and completed standard temozolomide…
- Conditions
- Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Trial name
- ELEVATE (NCT02366728)
- Testing
- Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Cytomegalovirus Infection
Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
This is an international, multi-center, double-blind, placebo-controlled evaluation valganciclovir treatment for up to 54 children (up to 4 years of age) with virologically-confirmed congenital CMV infection and hearing loss.
- Trial name
- NCT01649869
- Testing
- Valganciclovir
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
To determine whether cidofovir (HPMPC) therapy administered by intravenous infusion can extend the time to progression of peripheral cytomegalovirus (CMV) retinitis in AIDS patients.
- Trial name
- NCT00002437
- Testing
- Cidofovir, Probenecid
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Cytomegalovirus Infections, HIV Infections
A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT) when given in combination. Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with…
- Trial name
- NCT00000995
- Testing
- Zidovudine, Ganciclovir
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
the existing anti-CMV drugs mainly include valganciclovir, ganciclovir and foscarnet sodium, all of which act on DNA polymerase (pUL54), making them prone to cross resistance.
- Trial name
- CAPS01 (NCT07266467)
- Testing
- Letermovir, Valganciclovir
- Where
- China
- Volunteers
- 290 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT
To evaluate the efficacy and safety of secondary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese haplo-HSCT patients, as well as treatment-related mortality, all-cause…
- Trial name
- NCT05914701
- Testing
- Letermovir for secondary prophylaxis
- Volunteers
- 31 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cytomegalovirus Infection
Study of Prophylactic Vs Preemptive Valganciclovir
This is a study of prophylactic Vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients looking at clinical and pharmacoeconomic outcomes
- Trial name
- NCT00374686
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Cytomegalovirus Infections, HIV-1-infection
Cytomegalovirus Infection in Patients With HIV-1 Infection
The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (< 50 copies/ml) for at least 2 years and to…
- Trial name
- ACTHIV (NCT04067869)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 392 people
- Sponsor
- University Hospital, Bordeaux